LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListCatalent Inc

Catalent Inc

Closed

56.96 0.35

Overview

Share price change

24h

Current

Min

56.52

Max

57

Key metrics

By Trading Economics

Income

509M

-206M

Sales

42M

1B

EPS

-0.24

Profit margin

-20.117

Employees

17,800

EBITDA

-64M

22M

Recommendations

By TipRanks

Rating Consensus

Neutral

12 Months Forecast

+7.05 upside

Dividends

By Dow Jones

Next earnings

10 Jun 2024

Market Stats

By TradingEconomics

Market Cap

92M

10B

Previous open

56.61

Previous close

56.96

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Catalent Inc chart

Related News

5 Feb 2024, 14:50 UTC

Acquisitions, Mergers, TakeOvers

Novo Holdings to Buy Catalent for $11.5 Billion in Cash -- 4th Update

5 Feb 2024, 13:11 UTC

Acquisitions, Mergers, TakeOvers

Novo Holdings to Buy Catalent for $11.5 Billion in Cash -- 3rd Update

5 Feb 2024, 12:09 UTC

Acquisitions, Mergers, TakeOvers

Novo Holdings to Buy Catalent in $16.5 Billion Deal -- 2nd Update

5 Feb 2024, 11:38 UTC

Acquisitions, Mergers, TakeOvers

Novo Nordisk Buys Manufacturing Sites as Part of Novo Holdings' Acquisition of Catalent

5 Feb 2024, 11:31 UTC

Acquisitions, Mergers, TakeOvers

Novo Holdings Buying Catalent in $16.5 Billion Deal -- Update

5 Feb 2024, 11:23 UTC

Acquisitions, Mergers, TakeOvers

Novo Holdings Buying Catalent in $16.5 Billion Deal

23 Mar 2024, 13:00 UTC

Top News

U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies -- Heard on the Street -- WSJ

5 Feb 2024, 18:04 UTC

Acquisitions, Mergers, TakeOvers

Wegovy Maker to Boost Production Capacity With Multibillion-Dollar Deal -- WSJ

5 Feb 2024, 17:27 UTC

Earnings
Acquisitions, Mergers, TakeOvers

Novo Nordisk Makes the Latest Big Pharma Deal. Why More Are Coming. -- Barrons.com

5 Feb 2024, 15:36 UTC

Acquisitions, Mergers, TakeOvers

Novo Nordisk To Up Production Capacity As Parent Buys Catalent -- IBD

5 Feb 2024, 11:38 UTC

Acquisitions, Mergers, TakeOvers

Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk -- Barrons.com

5 Feb 2024, 11:15 UTC

Acquisitions, Mergers, TakeOvers

Novo Nordisk's Controlling Shareholder To Buy Catalent For $16.5 Billion -- MarketWatch

5 Feb 2024, 11:08 UTC

Acquisitions, Mergers, TakeOvers

Novo Nordisk: Manufacturing Sites Are in Italy, Belgium and US

5 Feb 2024, 11:08 UTC

Acquisitions, Mergers, TakeOvers

Novo Nordisk Buys Sites From Novo Holdings as Part of Novo Holdings' Deal to Buy Catalent

5 Feb 2024, 11:06 UTC

Acquisitions, Mergers, TakeOvers

Novo Nordisk Agrees to Buy Three Manufacturing Sites For Upfront Payment of $11 Bln

5 Feb 2024, 11:03 UTC

Acquisitions, Mergers, TakeOvers

Catalent: Merger Is Expected to Close Towards the End of Calendar Yr 2024 >CTLT

5 Feb 2024, 11:02 UTC

Acquisitions, Mergers, TakeOvers

Catalent: Of Co's More Than 50 Global Sites, Novo Holdings Intends to Sell Three Catalent Fill-Finish Sites and Related Assets Acquired in Merger to Novo Nordisk >CTLT

14 Apr 2023, 20:16 UTC

Earnings

JPMorgan, Citigroup, Boeing, Spirit AeroSystems, Catalent, and More Market Movers -- Barrons.com

Peer Comparison

Price change

Catalent Inc forecast

Price Target

By TipRanks

7.05% upside

12 Months Forecast

Average 60.75 USD  7.05%

High 63.5 USD

Low 47 USD

Based on 7 Wall Street analysts offering 12 month price targets for Catalent Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

7 ratings

1

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

56.52 / 57.07 Support&Resistance

Short Team

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Catalent Inc

Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.